Response and median time to neutrophil and platelet recovery, for those achieving remission, by pravastatin dose
| Dose, mg/d . | No. . | New . | CR/CRp . | Resistant . | Early death . | Days to PMN level greater than 1 × 109/L* . | Days to platelet count greater than 100 × 109/L* . |
|---|---|---|---|---|---|---|---|
| 40 | 3 | 2 | 1 | 1† | 1 | 25 | CRp |
| 80 | 3 | 3 | 2 | 1 | 0 | 32 | 28 |
| 160 | 3 | 3 | 3 | 0 | 0 | 34.33 | 28.33 |
| 320 | 3 | 2 | 2 | 0 | 1 | 36 | 50 |
| 480 | 3 | 1 | 2 | 1 | 0 | 46.5 | 35 |
| 640 | 3 | 0 | 1 | 2 | 0 | 43.5 | CRp |
| 880 | 4 | 1 | 1 | 1 | 2 | 26 | 24 |
| 1080 | 6 | 1 | 3 | 3 | 0 | 43.25 | 29 |
| 1280 | 3 | 0 | 1 | 2 | 0 | 42 | 45 |
| 1480 | 3 | 1 | 3 | 0 | 0 | 32.3 | 28 |
| 1680 | 3 | 1 | 1 | 2 | 0 | 20 | 25 |
| Total | 37 | 15 | 20 | 13 | 4 | 38 | 33 |
| Dose, mg/d . | No. . | New . | CR/CRp . | Resistant . | Early death . | Days to PMN level greater than 1 × 109/L* . | Days to platelet count greater than 100 × 109/L* . |
|---|---|---|---|---|---|---|---|
| 40 | 3 | 2 | 1 | 1† | 1 | 25 | CRp |
| 80 | 3 | 3 | 2 | 1 | 0 | 32 | 28 |
| 160 | 3 | 3 | 3 | 0 | 0 | 34.33 | 28.33 |
| 320 | 3 | 2 | 2 | 0 | 1 | 36 | 50 |
| 480 | 3 | 1 | 2 | 1 | 0 | 46.5 | 35 |
| 640 | 3 | 0 | 1 | 2 | 0 | 43.5 | CRp |
| 880 | 4 | 1 | 1 | 1 | 2 | 26 | 24 |
| 1080 | 6 | 1 | 3 | 3 | 0 | 43.25 | 29 |
| 1280 | 3 | 0 | 1 | 2 | 0 | 42 | 45 |
| 1480 | 3 | 1 | 3 | 0 | 0 | 32.3 | 28 |
| 1680 | 3 | 1 | 1 | 2 | 0 | 20 | 25 |
| Total | 37 | 15 | 20 | 13 | 4 | 38 | 33 |
CRp indicates that complete remission criteria were met except that platelet count was less than 100 × 109/L.
The median time to neutrophil recovery to greater than 1.0 × 109/L and platelet recovery to greater than 100 × 109/L in the historical population of newly diagnosed patients receiving Ida-HDAC was 29 days. The times listed for this study begin with day 1 as the first day of pravastatin, not the first day of Ida-HDAC, so for accurate comparison 32 days would be the mean time to recovery for the historical group.
One patient at this dose level, with myelofibrosis transformed to AML, had prolonged aplasia and could not receive additional therapy. Leukemia recurred 95 days after starting therapy.